| Lori Bichler, FNP-C | |
|
612 Center Ave N, Ashley, ND 58413-7013 | |
| (701) 288-3448 | |
| (701) 288-3213 |
| Full Name | Lori Bichler |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Experience | 26 Years |
| Location | 612 Center Ave N, Ashley, North Dakota |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1295840395 | NPI | - | NPPES |
| 19597 | Medicaid | ND |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | R25524 (North Dakota) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Ashley Medical Center | Ashley, ND | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Ashley Medical Center | 8628981834 | 7 |
News Archive
The Global Health Innovative Technology Fund has awarded the University of Florida and partners in the United States and Japan $3.2 million to advance a promising vaccine to prevent transmission of malaria.
A drug prescribed for the prevention of osteoporosis reduced women's risk of mild cognitive impairment by 33 percent in a worldwide clinical trial led by researchers at San Francisco VA Medical Center (SFVAMC).
Researchers at the University of North Carolina at Chapel Hill and Vanderbilt University Medical Center have synthetically reconstructed the bat variant of the SARS coronavirus (CoV) that caused the SARS epidemic of 2003.
SARcode Corporation presented data today for their lead investigational molecule, SAR 1118. In a Phase 2 dry eye trial, subjects receiving SAR 1118 demonstrated a reduction in corneal staining, increased tear production, and improved visual-related function as compared to placebo. These data were part of the scientific program of the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting held in Fort Lauderdale, Florida.
› Verified 8 days ago
| Entity Name | Ashley Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1851335830 PECOS PAC ID: 8628981834 Enrollment ID: O20040423001213 |
News Archive
The Global Health Innovative Technology Fund has awarded the University of Florida and partners in the United States and Japan $3.2 million to advance a promising vaccine to prevent transmission of malaria.
A drug prescribed for the prevention of osteoporosis reduced women's risk of mild cognitive impairment by 33 percent in a worldwide clinical trial led by researchers at San Francisco VA Medical Center (SFVAMC).
Researchers at the University of North Carolina at Chapel Hill and Vanderbilt University Medical Center have synthetically reconstructed the bat variant of the SARS coronavirus (CoV) that caused the SARS epidemic of 2003.
SARcode Corporation presented data today for their lead investigational molecule, SAR 1118. In a Phase 2 dry eye trial, subjects receiving SAR 1118 demonstrated a reduction in corneal staining, increased tear production, and improved visual-related function as compared to placebo. These data were part of the scientific program of the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting held in Fort Lauderdale, Florida.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Lori Bichler, FNP-C Po Box 450, Ashley, ND 58413-0450 Ph: (701) 288-3448 | Lori Bichler, FNP-C 612 Center Ave N, Ashley, ND 58413-7013 Ph: (701) 288-3448 |
News Archive
The Global Health Innovative Technology Fund has awarded the University of Florida and partners in the United States and Japan $3.2 million to advance a promising vaccine to prevent transmission of malaria.
A drug prescribed for the prevention of osteoporosis reduced women's risk of mild cognitive impairment by 33 percent in a worldwide clinical trial led by researchers at San Francisco VA Medical Center (SFVAMC).
Researchers at the University of North Carolina at Chapel Hill and Vanderbilt University Medical Center have synthetically reconstructed the bat variant of the SARS coronavirus (CoV) that caused the SARS epidemic of 2003.
SARcode Corporation presented data today for their lead investigational molecule, SAR 1118. In a Phase 2 dry eye trial, subjects receiving SAR 1118 demonstrated a reduction in corneal staining, increased tear production, and improved visual-related function as compared to placebo. These data were part of the scientific program of the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting held in Fort Lauderdale, Florida.
› Verified 8 days ago
Nina Klein, FNP-C Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 612 Center Ave N, Ashley, ND 58413 Phone: 701-288-3448 Fax: 701-288-3213 |